Dear All, See below my signature: A 6-month consultancy with WHO to support the the SECURE initiative, a program to assist countries in accessing and sustainably managing new and existing antibiotics needed to cope with antimicrobial resistance (AMR). There’s not much online (yet) about SECURE: the best description I can find is in the Terms of Reference
Dear All: In my inbox this morning is a posting from WHO of a part-time consultancy running from 15 Oct 2018 to 14 Oct 2019 to assist with TPPs for AMR products. The description is: The purpose of the consultancy is to assist the WHO Innovation Access and Use (IAU) Unit in the development of target product
Dear All, WHO have today updated their 2019 clinical/preclinical pipeline review by releasing their 2020 analyses of both the clinical and pre-clinical antibacterial product pipelines (the new 2020 report, the press release). Their 2020 review of antibacterial products in Phase 1 and beyond covers both traditional (n = 43) and non-traditional products (n = 27)
Dear All: Two useful papers have just been released — see titles and abstracts below my signature. Both are Open Access so please do download & read! And just for full disclosure, know that I’m a co-author on both. First, a working group organized by WHO has produced a comprehensive review of the clinical antimicrobial pipeline for both
Dear All, Today’s topics all share the theme of Less Talk, More Action! Here we go… First up … news from the US. I’ve written before about tweets from US CMS (Centers for Medicare and Medicare Services) administrator Seema Verma (link) on the need for changes in antibiotic reimbursement as well as the very concrete steps taken in
Dear All, WHO today published a Request for Proposals (RFP) for a consultant to develop an online e-learning course on antimicrobial stewardship! There is a mention of the request on the WHO AMR homepage (link) which in turn takes you to the extended details in this Terms of Reference document (link). In brief, the project
Dear All: I wrote previously (link to newsletter) about WHO’s call for information about pre-clinical antibiotic R&D. With a due date of 18 Mar, this is your chance to help construct a survey that can be used to drive further initiatives. In support of this, WHO is now look for a contractor to work with
Dear All: Are you doing preclinical antibiotic R&D? If so, WHO wants to hear from you! As you know, WHO has published these two analyses of priority pathogens and antibacterial agents currently in Phases 1-3: Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug resistant bacterial infections, including tuberculosis (2017, link)
(15 Apr 2021 update: WHO have today released a 2020 update to the report discussed in this newsletter.) Dear All, WHO has today released two exhaustive reviews of the antibacterial R&D universe (and by way of full disclosure, let me say upfront that I participated in the clinical pipeline discussion). Based on a cut-off date
Dear All, As you know, WHO has been driving a series of clinical and preclinical pipeline reviews (go here for my current master list of pipeline reviews, including links to the 2017 and 2019 WHO reviews). In support of the next iteration of this review process, WHO have now posted (go here) a Geneva-based consultancy
Using ideas to connect, create, and inspire
Supported by the Wellcome Trust